Late to the CAR-T Game, AstraZeneca Quietly Works on Its Own Off-the-Shelf Therapies

While AstraZeneca may be a major player in the oncology space, the company has been noticeably absent as the first wave of CAR-T therapies hit the market over the past five years. But movement is happening behind the scenes.